Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Rallybio (Nasdaq: RLYB) announced a webcast to provide updates on RLYB116, their once-weekly subcutaneously injected C5 inhibitor being developed for complement-mediated diseases. The webcast, scheduled for December 2, 2024, at 8:30 AM ET, will cover manufacturing process improvements, biomarker characterization analyses, and future program plans. The presentation will be accessible through Rallybio's investor website, with materials remaining available for 30 days afterward.
Rallybio (Nasdaq: RLYB) ha annunciato un webcast per fornire aggiornamenti su RLYB116, il loro inibitore C5 iniettato sottocutaneamente una volta a settimana, sviluppato per le malattie mediate dal complemento. Il webcast, previsto per il 2 dicembre 2024, alle 8:30 AM ET, tratterà miglioramenti nel processo di produzione, analisi di caratterizzazione dei biomarcatori e piani futuri del programma. La presentazione sarà accessibile attraverso il sito degli investitori di Rallybio, con i materiali disponibili per 30 giorni successivi.
Rallybio (Nasdaq: RLYB) anunció un webcast para proporcionar actualizaciones sobre RLYB116, su inhibidor de C5 inyectado subcutáneamente una vez a la semana, que se está desarrollando para enfermedades mediadas por complementos. El webcast, programado para el 2 de diciembre de 2024, a las 8:30 AM ET, cubrirá mejoras en el proceso de fabricación, análisis de caracterización de biomarcadores y planes futuros del programa. La presentación estará accesible a través del sitio web de inversores de Rallybio, y los materiales estarán disponibles durante 30 días después.
Rallybio (Nasdaq: RLYB)는 보완 매개 질환을 위해 개발 중인 주 1회 피하 주사 C5 억제제 RLYB116에 대한 업데이트를 제공하기 위한 웹캐스트를 발표했습니다. 이 웹캐스트는 2024년 12월 2일 오전 8시 30분 ET에 예정되어 있으며, 제조 공정 개선, 바이오 마커 특성 분석 및 향후 프로그램 계획에 대해 다룰 것입니다. 발표는 Rallybio의 투자자 웹사이트를 통해 접근 가능하며, 자료는 이후 30일 동안 제공될 것입니다.
Rallybio (Nasdaq: RLYB) a annoncé un webinaire pour fournir des mises à jour sur RLYB116, leur inhibiteur C5 injecté sous-cutanément une fois par semaine, en cours de développement pour les maladies médiées par le complément. Le webinaire, prévu pour le 2 décembre 2024 à 8h30 ET, couvrira les améliorations du processus de fabrication, les analyses de caractérisation des biomarqueurs et les futurs plans du programme. La présentation sera accessible via le site des investisseurs de Rallybio, et le matériel restera disponible pendant 30 jours après.
Rallybio (Nasdaq: RLYB) kündigte ein Webcast an, um Updates zu RLYB116, ihrem subkutan einmal wöchentlich injizierten C5-Inhibitor, der für komplementvermittelte Krankheiten entwickelt wird, bereitzustellen. Der Webcast, der für den 2. Dezember 2024 um 8:30 Uhr ET geplant ist, wird Verbesserungen im Produktionsprozess, Analysen zur Charakterisierung von Biomarkern und zukünftige Programmpläne behandeln. Die Präsentation wird über die Investorenseite von Rallybio zugänglich sein, und die Materialien bleiben 30 Tage lang verfügbar.
- None.
- None.
-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time --
Webcast Information
The live webcast may be accessed by visiting Rallybio’s website at http://investors.rallybio.com. A replay and accompanying slides of the webcast will be available on the Rallybio website for 30 days following the event.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 inhibitor that has the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241122010570/en/
Investors
Samantha Tracy
Rallybio Corporation
(475) 47-RALLY (Ext. 282)
investors@rallybio.com
Kevin Lui
Precision AQ
(212) 698-8691
kevin.lui@precisionaq.com
Media
Victoria Reynolds
Mission North
(760) 579-2134
rallybio@missionnorth.com
Source: Rallybio Corporation
FAQ
When is Rallybio's RLYB116 program update webcast scheduled for?
What will be discussed in Rallybio's RLYB116 program update?
How can investors access Rallybio's RLYB116 program update webcast?
What is RLYB116 being developed for?
